The House of Representatives has ordered an investigation into the spread of hepatitis in the country, even as it called for ...

The report by the WHO and the Federal Ministry of Health suggested that more than 20 million people, representing more than 10 per cent of Nigeria’s population, are living with chronic infection of ...

RNA and traditional virological biomarkers in patients with antiviral treatment-naïve chronic hepatitis B virus (HBV) infection. Methods: Serum HBV RNA, HBV DNA, hepatitis B surface antigen (HBsAg), ...

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients ...

Background To determine clinical-pathologic variables in patients with a new diagnosis of hepatocellular carcinoma (HCC) and underlying hepatitis B vs. C infection. Methods Patients presenting to ...

Gabow, I.A. and Mohamed, A.A. (2025) Assessment of Knowledge, Attitude and Vaccination Status of Hepatitis B Infection among Medical University Students in Mogadishu-Somalia. Journal of Biosciences ...

Several hospitals and nursing homes, especially in the private sector, are reportedly facing a shortage of hepatitis B ...

HBV infection is a significant biological risk for healthcare workers (HCW), as HCW are exposed to human fluids and consequently to blood-borne pathogens. Prior to the introduction of the ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE ...